Actively Recruiting
Safety and Exposure Study of Oral Probiotic R-5780 with PD-1 Inhibitors in Patients with Solid Tumors
Led by Rise Therapeutics LLC · Updated on 2026-09-18
33
Participants Needed
2
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety and tolerability of an oral probiotic called R-5780 in patients with solid tumors who are currently receiving PD-1 pathway checkpoint inhibitor therapy. This study focuses on patients with various cancers such as melanoma, basal cell carcinoma, squamous cell carcinoma, and other solid tumors that are refractory to immune checkpoint inhibitor treatment. The goal is to evaluate how R-5780 interacts with this therapy and affects patients overall health and tumor status. Participants will take R-5780 orally and report on their overall well-being. The study will also involve physician assessments of tumor status and laboratory evaluations including blood and fecal tests to measure inflammation and levels of the probiotic in stool samples. This is a single-group, open-label study where all participants receive the probiotic alongside their ongoing PD-1 inhibitor treatment. During the study, participants will be monitored for adverse events related to R-5780 over a 4-week period, with quality of life measured through a scale from the start of the study through day 112. Evaluations include imaging scans to assess tumor response and laboratory tests to track inflammation and probiotic levels. The study involves ongoing assessments of safety, tolerability, and clinical activity, continuing until study completion in September 2029.
CONDITIONS
Brief Title
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Research Team
J
Janet Stephens, PhD
C
Christian Freguia, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here